Lowering heart disease and cancer risk by treating inflammation; a health idea pioneered by complimentary health providers goes mainstream.

  • Share:
  • facebook
  • linkedin
  • twitter

Lowering heart disease and cancer risk by treating inflammation; a health idea pioneered by complimentary health providers goes mainstream.

For years, naturopathic doctors, nutritionists, chiropractors and other naturally based healthcare practitioners have suggested that the medical literature shows most diseases are inflammation based.  Heart disease and cancer are two of the most common, yet we are led to believe by most doctors that heart disease is a cholesterol problem, and cancer and inflammatory conditions cause most auto immune, heart attack and other disease processes.

Many complimentary providers have suggested Omega 3’s and Turmeric or Curcumin, the active ingredient in Turmeric as a way to reduce overall systemic inflammation, while we stay away from inflammatory foods.  Certain foods such as sugar and wheat can cause inflammation.

A recent NY Times article reported that big pharma is now taking notice and using a less natural medicinal approach to attack inflammation with an undoubtedly higher price tag. Isn’t it time that complimentary providers who take a holistic approach to inflammation and its affects on your body systems get taken more seriously and become covered under most insurance plans.  Check it out here

Drug Aimed at Inflammation May Lower Risk of Heart Disease and Cancer
By DENISE GRADYAUG. 27, 2017

A drug that fights inflammation can reduce the risk of heart attacks and strokes, and possibly lung cancer, in people who have already had one heart attack and are at high risk for another, a new study finds.

Researchers outside the study say the findings represent a major milestone — proof of a biologic concept that opens the door to new ways of treating and preventing cardiovascular disease in people who are still at risk despite standard therapies.

“This is fantastic,” said Dr. David J. Maron, the director of preventive cardiology at Stanford University School of Medicine. “The green light just went on for full-fledged investigation and development of effective and cost-effective new therapies.”

Read more